4T1-Luc Cells
CAD$1,104.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | 4T1-Luc is a genetically engineered variant of the murine 4T1 mammary carcinoma cell line, stably transduced to express the firefly luciferase reporter gene. The parental 4T1 cell line is derived from a spontaneously arising mammary tumor in a mouse and is widely used as a model of stage IV triple-negative breast cancer. It closely mimics human disease in its aggressive growth, poor differentiation, and high metastatic potential, with the ability to spontaneously disseminate from the primary tumor site to distant organs such as lung, liver, bone, and brain. The luciferase-expressing derivative retains these core biological characteristics while enabling non-invasive tracking of tumor progression. The introduction of the luciferase gene allows for sensitive bioluminescence imaging (BLI) following administration of a luciferin substrate, providing a quantitative and longitudinal readout of tumor burden in live animals. This modification enables real-time monitoring of primary tumor growth, metastatic spread, and therapeutic response without the need for invasive procedures. The luciferase signal correlates with viable cell number, making 4T1-Luciferase particularly useful for in vivo studies of metastasis, tumor kinetics, and drug efficacy in syngeneic immunocompetent mouse models. Stable integration ensures consistent reporter expression across passages, although signal intensity may vary depending on clone selection and experimental conditions. 4T1-Lucmaintains the immunological and metastatic properties of the parental line, including resistance to many chemotherapeutic agents and the ability to interact with and modulate the host immune system. This makes it especially valuable for studies of tumor immunology, immune checkpoint therapies, and combination treatment strategies. The addition of a bioluminescent reporter significantly enhances experimental throughput and sensitivity, supporting applications in preclinical drug development, metastatic modeling, and real-time assessment of therapeutic interventions in breast cancer research. |
|---|---|
| Organism | Mouse |
| Tissue | Mammary gland |
| Disease | Malignant neoplasms |
Characteristics
| Breed/Subspecies | BALB/cfC3H |
|---|---|
| Gender | Female |
| Morphology | Epithelial-like |
| Growth properties | Adherent |
Regulatory Data
| Citation | 4T1-Luc (Cytion catalog number 305663) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 10090 |
| CellosaurusAccession | CVCL_J239 |
Biomolecular Data
| Antigen expression | Luc |
|---|---|
| Tumorigenic | Yes, in BALB/c mice. |
| MSI-status |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Seeding density | 1 to 3 x 104 cells/cm2 |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |